Bringing the Oncology Community Together

Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments

Merav Bar, MD
Published Online: Thursday, January 2, 2014
Seattle Cancer Care AllianceDr. Merav Bar
Merav Bar, MD
 
Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Assistant Professor, Medical Oncology Division, University of Washington
Seattle Cancer Care AllianceSeattle Cancer Care Alliance
Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers. These new T-cell therapies are primarily being tested in clinical trials involving patients with highrisk leukemia or lymphoma before or after bone marrow transplant (BMT).

Preventing Relapse in Adults After Allogeneic BMT for Lymphoid Malignancies

Approved by the FDA last year, CD19-specific Donor T Cells for B-Cell Malignancies After Allogeneic Transplant is a phase I/II trial designed to boost the graft-versus-tumor effect in subgroups of adults with acute lymphocytic leukemia, chronic lymphocytic leukemia, or diffuse large B-cell lymphoma who have received an allogeneic BMT from a matched related donor, thereby reducing the risk of posttransplant relapse.

After their transplant, patients will receive engineered T cells, generated from the donor’s blood. A lentiviral vector inserts a gene that encodes a chimeric antigen receptor (CAR), which is half monoclonal antibody and half T-cell receptor, that targets the CD19 molecule expressed exclusively on B cells (both malignant and normal). CARs are hard-wired to bind to the tumor cell without regard to the patient’s HLA status. This is important because it allows a single pre-constructed CAR to target tumors in patient populations with diverse HLA patterns. Once they bind to the target, the T cells automatically trigger cytotoxicity.

“We are coupling the exquisite specificity of the antibody to the potent effector functions of the T cell,” said Stanley R. Riddell, MD, oncology and immunology researcher at Fred Hutchinson Cancer Research Center. “We target the tumor with the antibody and kill it with the T cell. Moreover, since this is a living therapy, the engineered cells can grow in the patient until the tumor is eradicated.”

SCCA researchers enrich the donor’s T-cell population with longer-lasting central memory cell subsets to encourage the T cells to persist in the patient.

Engineered T-cell therapy has potential for the treatment of patients with B-cell malignancies, but more work is needed to make the responses durable. Using central memory cells as a starting population for expansion might enable transferred T cells to provide long-lasting antitumor effects.

Preventing or Treating Relapse After BMT for AML, MDS, or CML

This phase I/II trial has two arms: (1) prophylactic T-cell therapy for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML) patients with high risk of relapse after BMT, and (2) treatment with T cells for AML/MDS/ CML patients with either minimal residual disease or full hematologic relapse after BMT.

The strategy involves genetically engineering donor-derived T cells to express a T-cell receptor specific to WT1, a protein that is highly expressed on leukemia cells. The magnitude of WT1 expression correlates with the cancer’s aggressiveness. The gene that encodes the high affinity WT1 T-cell receptor has been isolated from a healthy individual with human leukocyte antigen (HLA)-A*0201 and cloned into a lentiviral vector, which is then used to transduce donor-derived T cells. For this to work, the patient must have the proper matching HLA-A*0201 marker.

This HLA marker was chosen because it is common in the overall population, seen in about a third of Caucasians. Eventually an array of lentiviral vectors will allow treatment of any HLA type.

Researchers targeted the WT1 antigen based on a recent SCCA study (Sci Transl Med. 2013;5[174]:174ra27) showing antileukemic activity without significant main organ toxicity or graft-versus-host disease in patients receiving WT1-specific donor-derived CD8+ cytotoxic T cells after BMT for high-risk leukemia. These were not engineered but naturally occurring anti-WT1 T cells that were carefully isolated from the donor’s lymphocytes, grown in culture, and given to the patient. At the time of the study’s publication, four patients with the best responses were still alive with no recurrence of their cancer more than 2 years after transplant.

Page: 12Next Page (2) >>
Related Articles
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Epizyme Maintains Independence, Advances HMT-Inhibitor Platform
Epizyme, a Cambridge, Massachusetts-based biotech, opted for independence, with a successful IPO in 2013.
MSK's CAR Trials Halted Temporarily Amid Safety Review
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?
To address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targeted specifically to minorities.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.